Ikarian Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ikarian Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-75	Closed	-$17.3K	–	162
2023 Q2	$17.3K	Hold	75	–	–	﹤0.01%	121
2023 Q1	$18.2K	Hold	75	–	–	﹤0.01%	115
2022 Q4	$21.8K	Buy	+75	New	+$7.33K	0.01%	82
2022 Q1	–	Sell	-23,700	Closed	-$2.01M	–	207
2021 Q4	$2.01M	Hold	23,700	–	–	0.3%	62
2021 Q3	$1.89M	Buy	23,700 +46	+0.2%	+$3.97K	0.13%	128
2021 Q2	$2.3M	Hold	23,654	–	–	0.19%	122
2021 Q1	$2.77M	Hold	23,654	–	–	0.09%	178
2020 Q4	$2.63M	Hold	23,654	–	–	0.12%	139
2020 Q3	$2.81M	Sell	23,654 -18,900	-44%	-$2.05M	0.2%	94
2020 Q2	$4.82M	Buy	42,554 +2,220	+6%	+$218K	0.38%	68
2020 Q1	$2.69M	Sell	40,334 -4,436	-10%	-$370K	0.2%	85
2019 Q4	$4.08M	Buy	+44,770	New	+$4.34M	0.66%	43

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's MDGL Position: Q3 2023 in Review

Ikarian Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 75 shares — an estimated $17.3K sold.

Ikarian Capital first reported a position in MDGL in Q4 2019 and held it in 12 quarters. The position peaked at $4.82M in Q2 2020. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

Ikarian Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 75 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $17.3K.
Ikarian Capital first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 12 quarters.
Ikarian Capital's Madrigal Pharmaceuticals position peaked at $4.82M in Q2 2020.
205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.